BAYN Stock Overview
Together its subsidiaries, operates as a life science company worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €26.38 |
52 Week High | €42.58 |
52 Week Low | €24.96 |
Beta | 0.97 |
11 Month Change | -5.55% |
3 Month Change | 0.44% |
1 Year Change | -36.41% |
33 Year Change | -45.42% |
5 Year Change | -60.36% |
Change since IPO | 93.66% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively
Sep 13Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now
Aug 09These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively
Jun 11The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet
May 07These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way
Jan 18Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?
Dec 27Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt
Oct 15Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate
Aug 05Is Bayer (ETR:BAYN) A Risky Investment?
Jun 28Shareholder Returns
BAYN | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0.4% | 3.7% | 1.1% |
1Y | -36.4% | -7.6% | 18.9% |
Return vs Industry: BAYN underperformed the German Pharmaceuticals industry which returned -7.6% over the past year.
Return vs Market: BAYN underperformed the German Market which returned 18.9% over the past year.
Price Volatility
BAYN volatility | |
---|---|
BAYN Average Weekly Movement | 5.2% |
Pharmaceuticals Industry Average Movement | 8.1% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.8% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BAYN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BAYN's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1863 | 96,567 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
BAYN fundamental statistics | |
---|---|
Market cap | €25.91b |
Earnings (TTM) | -€1.27b |
Revenue (TTM) | €47.11b |
0.5x
P/S Ratio-20.5x
P/E RatioIs BAYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BAYN income statement (TTM) | |
---|---|
Revenue | €47.11b |
Cost of Revenue | €19.98b |
Gross Profit | €27.13b |
Other Expenses | €28.40b |
Earnings | -€1.27b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 12, 2024
Earnings per share (EPS) | -1.29 |
Gross Margin | 57.59% |
Net Profit Margin | -2.69% |
Debt/Equity Ratio | 126.5% |
How did BAYN perform over the long term?
See historical performance and comparison